Jci_page_head_homepage_01 Jci_page_head_homepage_02
David Patsouris, Stéphane Mandard, Peter J. Voshol, Pascal Escher, Nguan Soon Tan, Louis M. Havekes, Wolfgang Koenig, Winfried März, Sherrie Tafuri, Walter Wahli, Michael Müller, Sander Kersten
Published in Volume 114, Issue 1
J Clin Invest. 2004; 114(1):94–103 doi:10.1172/JCI20468
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 5

PPARα activation decreases plasma and urine glycerol levels. Enzyme activity of GPDH (A) or glycerol kinase (B) was determined in liver homogenates of wild-type and PPARα-null mice after feeding with Wy14643 (n = 4 per group). Error bars represent SEM. (C) AQP3 protein was determined by Western blot in the membrane fraction of liver homogenates of wild-type and PPARα-null mice treated with Wy14643. Equal amounts of protein were loaded. Glycerol was determined in plasma (D) (n = 4) and urine (E) (samples in each group were pooled and determined in duplicate) in wild-type and PPARα-null mice after feeding with Wy14643. Significant effects were observed by two-way ANOVA for genotype and for Wy14643 treatment (P < 0.05). (F) Plasma glycerol levels decreased in atherosclerotic patients after 4-week treatment with micronized fenofibrate (FF) (250 mg/day). (P < 0.01, paired Student’s t test) (G) Correlation between changes in plasma free fatty acids (FFA) and glycerol in atherosclerotic patients treated with fenofibrate.